Gastrointestinal (GI): NSAIDs that block COX-1 action have correlations with GI difficulties due to inhibition from the synthesis of gastroprotective brokers like PGE2 along with other prostaglandins. This inhibition causes reduced mucin output by gastric epithelial cells, less bicarbonate secretion, and fewer epithelial mobile turnover, between other actions. This characteristic https://anthonyv223dzu9.blogolenta.com/profile